Product Details
| Product Name:
AC710 |
CAS No.:
1351522-04-7 |
| Purity:
99.48% |
Supply Ability:
10g |
| Release date:
2024/11/19 |
Product Introduction
Bioactivity
| Name | AC710 |
| Description | AC710 is a potent PDGFR inhibitor with Kds of 0.6 nM for FLT3, 1 nM for KIT, 1.57 nM for CSF1R, 1.3 nM for PDGFRα, and 1 nM for PDGFRβ. |
| Animal Research | The antitumor efficacy of AC710 is assessed in a subcutaneous flank-tumor xenograft model in athymic nude mice using the MV4-11cell line. AC710 is dosed at 0.3, 3, and 30 mg/kg for 2 weeks. Tumor growth and body weight are monitored. |
| In vivo | At a dosage of 0.3 mg/kg, AC710 transiently inhibits tumor growth, with rapid resumption following cessation. Doses of 3 and 30 mg/kg result in complete tumor regression and prolonged suppression of tumor volume post-treatment. Notably, administration of AC710 does not lead to bodyweight loss in treated animals across all tested doses. Further, AC710 significantly mitigates disease progression in a mouse collagen-induced arthritis (CIA) model in a dose-dependent manner, starting from a low dose of 3 mg/kg over a span of 15 days (day 0-14). At increased dosages of 10 and 30 mg/kg, AC710's effectiveness in reducing joint swelling and inflammation is comparable or slightly superior to that of dexomethasone administered at a safe dose. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 15 mg/mL (26.66 mM), Sonication and heating are recommended.
|
| Keywords | Fms like tyrosine kinase 3 | Cluster of differentiation antigen 135 | CD117 | Platelet-derived growth factor receptor | PDGFR | CD135 | Inhibitor | AC 710 | AC-710 | c-Kit | AC710 | FLT3 | SCFR | inhibit |
| Inhibitors Related | Gilteritinib | Nintedanib | Regorafenib monohydrate | Sorafenib | Pexidartinib | Dasatinib | Regorafenib | Sorafenib tosylate | Lenvatinib mesylate | Imatinib | Pazopanib | Axitinib |
| Related Compound Libraries | Anti-Lung Cancer Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Angiogenesis related Compound Library | Inhibitor Library | Bioactive Compounds Library Max | Covalent Inhibitor Library | Anti-Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:1351522-05-8
$1520.00 / 25mg
-
-
CAS:61-76-7
$73.00 / 500mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$1.00/1KG |
VIP6Y
|
Career Henan Chemical Co
|
2019-12-30 |
United States